APROGEN BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,565 KRW | -0.13% |
|
+5.03% | -46.03% |
| Sales 2022 | 65.19B 47.39M 3.79B | Sales 2023 | 87.36B 63.51M 5.09B | Capitalization | 191B 139M 11.1B |
|---|---|---|---|---|---|
| Net income 2022 | 7.84B 5.7M 456M | Net income 2023 | -118B -85.98M -6.88B | EV / Sales 2022 | 3.62 x |
| Net Debt 2022 | 35.66B 25.93M 2.08B | Net Debt 2023 | 171B 124M 9.95B | EV / Sales 2023 | 4.14 x |
| P/E ratio 2022 |
26.5
x | P/E ratio 2023 |
-1.55
x | Employees | 363 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.37% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.13% | ||
| 1 week | +5.03% | ||
| Current month | -17.63% | ||
| 1 month | -17.63% | ||
| 3 months | -17.63% | ||
| 6 months | -52.43% | ||
| Current year | -46.03% |
1 week
1 496.00
1 900.00
1 month
1 467.002 180.00
Current year
1 467.003 080.00
1 year
1 467.007 240.00
3 years
1 467.0014 000.00
5 years
1 467.0028 500.00
10 years
1 467.00100 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jung-Chool Kim
CEO | Chief Executive Officer | 67 | 31/03/12 |
Yun-Gyeong Bae
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Jong-Su Gang
BRD | Director/Board Member | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Chool Kim
CEO | Chief Executive Officer | 67 | 31/03/12 |
Jong-Su Gang
BRD | Director/Board Member | 60 | - |
Yun-Gyeong Bae
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1,565 | -0.13% | 160,348 |
| 25/04/24 | 1,567 | -2.25% | 195,606 |
| 24/04/24 | 1,603 | -3.43% | 964,410 |
| 23/04/24 | 1,660 | +9.35% | 5,072,144 |
| 22/04/24 | 1,518 | +1.88% | 260,277 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).
Sector
Pharmaceuticals
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -46.03% | 74.76M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A003060 Stock
